In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neck-and-Neck in Nephrology

Executive Summary

Nabi with PhosLo and Genzyme with Renagel now split the market for dialysis patients requiring treatment for high phosphate levels. Soon a third firm will enter the fray--the UK's Shire. Thus far, the marketing battle has been fought with nitty-gritty clinical data. But now Genzyme is raising the notion of "accumulation" to stigmatize competitors, while Nabi emphasizes the issue of cost. The competitive stakes are rising because Medicare changes in 2006 will dramatically expand the market.

You may also be interested in...

Ilypsa Inc.

Ilypsa is a spin-out of Symyx Technologies, a manufacturer of innovative materials for such industrial clients such as Dow Chemical and Agfa-Gevaert. The company had honed an ability to rapidly screen miniscule amounts of thousands of polymers for interesting functions. Symyx's founders quickly recognized that the company's platform was a potential therapeutic gold mine. Ilypsa was thus founded to focus on pharmaceutical applications.

Teva Debuts US Azopt Rival

Teva has launched the first and so far only US generic version of Novartis’ Azopt treatment for ocular hypertension, with the brinzolamide 1% solution having been developed and manufactured by Indoco Remedies.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts